2.12
0.02 (0.95%)
| Penutupan Terdahulu | 2.10 |
| Buka | 2.10 |
| Jumlah Dagangan | 2,354,673 |
| Purata Dagangan (3B) | 2,905,845 |
| Modal Pasaran | 721,357,568 |
| Harga / Jualan (P/S) | 61.33 |
| Harga / Buku (P/B) | 1.83 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Aug 2025 - 8 Aug 2025 |
| Margin Operasi (TTM) | -1,913.23% |
| EPS Cair (TTM) | -2.20 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.72% |
| Nisbah Semasa (MRQ) | 9.01 |
| Aliran Tunai Operasi (OCF TTM) | -157.34 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -64.76 M |
| Pulangan Atas Aset (ROA TTM) | -23.33% |
| Pulangan Atas Ekuiti (ROE TTM) | -119.66% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Nuvation Bio Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.63 |
|
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 19.12% |
| % Dimiliki oleh Institusi | 61.77% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Decheng Capital Llc | 31 Mar 2025 | 25,954,439 |
| Omega Fund Management, Llc | 31 Dec 2024 | 13,072,340 |
| Octagon Capital Advisors Lp | 31 Dec 2024 | 9,202,907 |
| Laurion Capital Management Lp | 31 Dec 2024 | 6,491,475 |
| Mpm Bioimpact Llc | 31 Dec 2024 | 4,164,178 |
| Aisling Capital Management Lp | 31 Dec 2024 | 2,541,009 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 10.00 (Jones Trading, 371.70%) | Beli |
| 10.00 (HC Wainwright & Co., 371.70%) | Beli | |
| Median | 8.00 (277.36%) | |
| Rendah | 5.00 (Wedbush, 135.85%) | Beli |
| Purata | 7.75 (265.57%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 2.12 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wedbush | 16 May 2025 | 5.00 (135.85%) | Beli | 2.26 |
| JMP Securities | 23 Apr 2025 | 6.00 (183.02%) | Beli | 2.08 |
| Jones Trading | 12 Mar 2025 | 10.00 (371.70%) | Beli | 2.24 |
| HC Wainwright & Co. | 10 Mar 2025 | 10.00 (371.70%) | Beli | 1.88 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |